What is RefleXion?
RefleXion is at the forefront of innovative cancer treatment, specializing in biotargeting oncology. Based in Hayward, California, the company offers advanced solutions in radiation therapy and life sciences, aiming to redefine patient care through precision targeting. Its technology is designed to address the complexities of cancer treatment, providing a more effective and targeted approach for patients. The company's commitment to innovation in oncology positions it as a key player in the life sciences sector.
How much funding has RefleXion raised?
RefleXion has raised a total of $587.6M across 8 funding rounds:
Series A
$11.6M
Series B
$6M
Series C
$100M
Unspecified
$60M
Private Equity
$100M
Private Equity
$80M
Debt
$125M
Other Financing Round
$105M
Series A (2014): $11.6M with participation from Sofinnova Partners and Venrock
Series B (2016): $6M led by Pfizer Venture Investments, Sofinnova Partners, KCK, and Venrock
Series C (2018): $100M supported by GT Healthcare Capital Partners, Venrock, Pfizer Venture Investments, Sofinnova Partners, The Rise Fund, and KCK
Unspecified (2019): $60M featuring Oxford Finance
Private Equity (2020): $100M backed by Public Sector Pension Investment Board
Private Equity (2022): $80M with participation from KCK Group, PSP Investments, The Rise Fund, and T. Rowe Price
Debt (2022): $125M led by Oxford Finance
Other Financing Round (2023): $105M supported by Pictet Asset Management, TPG, The Rise Fund, Squarepoint Capital, T. Rowe Price, Pfizer, Ally Bridge Group, and Johnson & Johnson
Key Investors in RefleXion
Pictet Asset Management
Pictet Asset Management is an investment management firm known for its financial culture and behind-the-scenes operations within the Pictet Group.
TPG
TPG is a global investment firm specializing in alternative assets and business growth, offering investment management, advisory, and capital solutions across private equity, credit, real estate, and impact investing.
The Rise Fund
The Rise Fund is an impact investing platform focused on growth-stage, mission-driven companies aligned with UN Sustainable Development Goals, investing across sectors like healthcare and climate.
What's next for RefleXion?
With the recent influx of major strategic investment, RefleXion is poised for accelerated expansion and further development of its groundbreaking biotargeting oncology platform. This substantial backing, part of its overall $587.6M in capital, indicates a strong market confidence in the company's technology and its potential to revolutionize cancer care. The company is expected to leverage this financing to enhance its research and development efforts, scale its operations, and broaden its market reach, solidifying its position as a leader in advanced radiation therapy and life sciences.
See full RefleXion company page
